Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.
Moudgal
Varsha
V
Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA.
Little
Tania
T
Boikov
Dina
D
Vazquez
Jose A
JA
D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000235:genetics; D000077336:Caspofungin; D026141:Drug Resistance, Multiple, Fungal; D054714:Echinocandins; D004586:Electrophoresis; D004696:Endocarditis / Q000188:drug therapy / Q000382:microbiology*; D005838:Genotype; D006350:Heart Valve Prosthesis / Q000382:microbiology*; D006801:Humans; D007621:Karyotyping; D055666:Lipopeptides; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000494:pharmacology*; D016459:Prosthesis-Related Infections / Q000382:microbiology*; D012008:Recurrence
D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin